Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis.
暂无分享，去创建一个
[1] K. Wahlin,et al. Effect of oral diclofenac intake on faecal calprotectin , 2016, Scandinavian journal of gastroenterology.
[2] D. Baeten,et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis , 2014, Arthritis Research & Therapy.
[3] D. Baeten,et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis , 2014, Annals of the rheumatic diseases.
[4] A. Gasbarrini,et al. Role of fecal calprotectin in gastrointestinal disorders. , 2013, European review for medical and pharmacological sciences.
[5] S. Targan,et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study , 2012, Arthritis Research & Therapy.
[6] D. Atar,et al. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. , 2012, American journal of hypertension.
[7] J. Brun,et al. S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity. , 2007, The Journal of rheumatology.